Skip to main content
Akari Therapeutics Plc logo

Akari Therapeutics Plc — Investor Relations & Filings

Ticker · AKTX ISIN · US00972G2075 US Manufacturing
Filings indexed 691 across all filing types
Latest filing 2026-03-30 Annual Report
Country US United States of America
Listing US AKTX

About Akari Therapeutics Plc

https://www.akaritx.com/

Akari Therapeutics Plc is an innovative targeted oncology company focused on developing next-generation antibody-drug conjugates (ADCs) and utilizing a novel discovery engine. The company's platform is built around proprietary cancer-killing toxins designed for targeted delivery to tumor cells. Its lead payload is PH1, which is engineered to create potent therapies for cancer treatment.

Recent filings

Filing Released Lang Actions
10-K - Akari Therapeutics Plc (0001541157) (Filer)
Annual Report
2026-03-30 English
8-K - Akari Therapeutics Plc (0001541157) (Filer)
Regulatory Filings
2026-03-17 English
8-K - AKARI THERAPEUTICS PLC (0001541157) (Filer)
Regulatory Filings
2026-03-02 English
DEF 14A Filing
Proxy Solicitation & Information Statement
2026-02-02 English
S-1 Filing
Registration Form
2026-01-23 English
4
Director's Dealing
2025-12-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.